Tracers / [177Lu]Lu-CHX-A''-DTPA-F8

[177Lu]Lu-CHX-A''-DTPA-F8

Also written as [Lu-177]Lu-CHX-A''-DTPA-F8
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
Stage
Reported once
Syntheses indexed
1

What it is

Compound class
Antibody-based radioimmunoconjugate (F8 antibody-CHX-A''-DTPA chelator construct)
Target / mechanism
Targets the extra domain A (EDA) of fibronectin, an extracellular matrix protein highly abundant in TNBC stroma PMID 41537706
Clinical application
Radioligand therapy for triple-negative breast cancer, targeting extracellular matrix (extra domain A of fibronectin) as part of an 89Zr/177Lu theranostic pair PMID 41537706
Theranostic pair

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesisSPE>95%p-SCN-Bn-CHX-A”-DTPA
Macrocyclics
41537706
2026 Clin Cancer Res
F8 at pH 8.5 was incubated with p-SCN-Bn-CHX-A”-DTPA (Macrocyclics #B-355, CAS #157380–45-5) in a 1:6 molar ratio at 37 °C and 300 rpm for 90 minutes. — [177Lu]Lu-CHX-A”-DTPA-F8 (referred to as 177Lu-F8) radiosynthesis yielded > 95% radiochemical conversion at specific activity up to 0.56 MBq/μg

Need this precursor?We can point you to suppliers for [177Lu]Lu-CHX-A''-DTPA-F8, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41537706. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41537706: 'p-SCN-Bn-CHX-A”-DTPA (Macrocyclics #B-355, CAS #157380–45-5)'.